Search

Allyn Timothy Londregan

from Barrington, RI
Age ~44
Get Report
Also known as:
Allyn T Londregan, Timothy J Londregan, Alan Londregan
Phone and address:
26 Chapel Rd, Barrington, RI 02806
Connected to:
Francis Londres, 62Thomas E Londres, 60Ali G Londrigan, 50Nancy R Londroche, 82Carolyn E Londry, 34John H Londt, 44Alan D Londy, 68Adriana C Lone, 45Ahsan M Lone, 32Mark K Lone, 66

Allyn Londregan Phones & Addresses

  • 26 Chapel Rd, Barrington, RI 02806
  • 4 Laurel Crest Dr, Waterford, CT 06385 (860) 442-7139
  • Philadelphia, PA

Resumes

Resumes

Allyn Londregan Photo 1

Principal Scientist At Pfizer

View page
Position:
Principal Scientist at Pfizer
Location:
Providence, Rhode Island Area
Industry:
Pharmaceuticals
Work:
Pfizer since Apr 2008
Principal Scientist
GlaxoSmithKline Aug 2006 - Apr 2008
Principal Scientist
Education:
University of Pennsylvania 2002 - 2006
Ph.D., Organic Chemistry Boston College 1998 - 2002
BS, Chemistry

Publications

Us Patents

Novel Seh Inhibitors And Their Use

View page
US Patent:
20100210655, Aug 19, 2010
Filed:
Oct 10, 2008
Appl. No.:
12/682068
Inventors:
Yun Ding - Waltham MA, US
Allyn T. Londregan - Barrington RI, US
International Classification:
A61K 31/53
C07D 403/14
C07D 403/04
A61P 9/00
A61P 1/16
A61P 11/06
A61P 3/10
A61P 3/04
US Classification:
514245, 544198, 544209
Abstract:
The invention is directed to novel sEH inhibitors and their use in the treatment of diseases mediated by the sEH enzyme. Specifically, the invention is directed to compounds according to Formula I:wherein R1, R2, R5a, R6a, A, B, Y, I, and m are defined below, and to pharmaceutically-acceptable salts thereof. The compounds of the invention are sEH inhibitors and can be used in the treatment of diseases mediated by the sEH enzyme, such as hypertension. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting sEH and treatment of conditions associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

Novel Seh Inhibitors And Their Use

View page
US Patent:
20100261743, Oct 14, 2010
Filed:
Dec 4, 2008
Appl. No.:
12/745018
Inventors:
Allyn T. Londregan - Barrington RI, US
John Jeffrey McAtee - King of Prussia PA, US
International Classification:
A61K 31/506
C07D 401/04
C07D 403/04
A61P 9/12
A61P 9/00
A61P 1/16
A61P 3/10
A61P 3/04
A61P 9/10
A61P 25/00
US Classification:
514275, 544331, 544328, 514257
Abstract:
The invention is directed to novel sEH inhibitors and their use in the treatment of diseases mediated by the sEH enzyme. Specifically, the invention is directed to compounds according to Formula I:wherein R1, R2a, R2b, Rya, R6a, A, B, K, L, M, Y, Z, l, and m are defined herein, and to pharmaceutically-acceptable salts thereof. The compounds of the invention are sEH inhibitors and can be used in the treatment of diseases mediated by the sEH enzyme, such as hypertension. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting sEH and treatment of conditions associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

2,3-Dihydro-1H-Inden-1-Yl-2,7-Diazaspiro[3.5] Nonane Derivatives

View page
US Patent:
20110230461, Sep 22, 2011
Filed:
Mar 16, 2011
Appl. No.:
13/049225
Inventors:
Samit K. Bhattacharya - Niantic CT, US
Kimberly O. Cameron - East Lyme CT, US
Dilinie P. Fernando - Niantic CT, US
Kim F. McClure - Mystic CT, US
Daniel W. Kung - Salem CT, US
Allyn T. Londregan - Barrington RI, US
Suvi T. M. Simila - Old Saybrook CT, US
International Classification:
A61K 31/397
C07D 401/14
C07D 471/10
A61P 3/00
A61P 9/00
US Classification:
51421016, 544230, 546 16
Abstract:
The present invention provides a compound of Formula (I)or a pharmaceutically salt thereof wherein R, R, Ra, L, Z, Zand Zare as defined herein, that act as Ghrelin antagonists or inverse agonists; pharmaceutical compositions thereof; and methods of treating diseases, disorders, or conditions mediated by the antagonism of the Ghrelin receptor.

2,3-Dihydro-1H-Inden-1-Yl-2,7-Diazaspiro[3.5]Nonane Derivatives

View page
US Patent:
20140080756, Mar 20, 2014
Filed:
Nov 18, 2013
Appl. No.:
14/083275
Inventors:
Kimberly O. Cameron - Cambridge MA, US
Dilinie P. Fernando - Niantic CT, US
Kim F. McClure - Mystic CT, US
Daniel W. Kung - Salem CT, US
Allyn T. Londregan - Barrington RI, US
Suvi T.M. Orr - San Diego CA, US
Assignee:
Pfizer Inc. - New York NY
International Classification:
C07D 471/10
A61K 31/506
A61K 31/53
A61K 31/435
A61K 31/497
C07D 491/056
C07D 513/04
A61K 45/06
US Classification:
514 48, 544230, 51421021, 546 16, 544184, 514 69, 514 72, 514 65
Abstract:
The present invention provides a compound of Formula (I)a pharmaceutically salt thereof wherein R, R, Ra, L, Z, Zand Zare as defined herein, that act as Ghrelin antagonists or inverse agonists; pharmaceutical compositions thereof; and methods of treating diseases, disorders, or conditions mediated by the antagonism of the Ghrelin receptor.

Combinations Comprising Benzodioxol As Glp-1R Agonists For Use In The Treatment Of Nash/Nafld And Related Diseases

View page
US Patent:
20220387402, Dec 8, 2022
Filed:
May 15, 2020
Appl. No.:
17/612672
Inventors:
- New York NY, US
Scott W. Bagley - Mystic CT, US
John M. Curto - Mystic CT, US
Matthew Dowling - Old Lyme CT, US
David James Edmonds - Riehen, CH
Dilinie Fernando - Jamaica Plain MA, US
Mark E. Flanagan - Gales Ferry CT, US
Kentaro Futatsugi - Sharon MA, US
David Andrew Griffith - Sudbury MA, US
Kim Huard - Berkeley CA, US
Gajendra Ingle - New Haven CT, US
Wenhua Jiao - Salem CT, US
Shawn M. LaCasse - Griswold CT, US
Yajing Lian - Waterford CT, US
Chris Limberakis - Pawcatuck CT, US
Allyn T. Londregan - Barrington RI, US
Alan M. Mathiowetz - Waltham MA, US
David Walter Piotrowski - Waterford CT, US
Roger B. Ruggeri - Waterford CT, US
Kristin Wiglesworth - Germantown MD, US
Assignee:
Pfizer Inc. - New York NY
International Classification:
A61K 31/438
A61K 31/496
A61K 31/4545
A61K 31/454
A61K 31/5377
A61K 31/506
A61K 31/46
A61K 45/06
A61K 38/26
A61K 38/28
A61K 38/17
A61P 1/16
Abstract:
In part, the invention provides a new combination comprising (1) a GLP-1R agonist and (2) an ACC inhibitor or a DGAT2 inhibitor, or a KHK inhibitor or FXR agonist. The invention further provides new methods for treating diseases and disorders, for example, fatty liver, nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, nonalcoholic steatohepatitis with liver fibrosis, nonalcoholic steatohepotitis with cirrhosis, and nonalcoholic steatohepatitis with cirrhosis and with hepatocellular carcinoma or with a metabolic-related disease, obesity, and type 2 diabetes, for example, using the new combination described herein.

(Aza)Benzothiazolyl Substituted Pyrazole Compounds

View page
US Patent:
20220184041, Jun 16, 2022
Filed:
Nov 23, 2021
Appl. No.:
17/533592
Inventors:
- New York NY, US
Daniel Paul Canterbury - Pawcatuck CT, US
Robert Lee Dow - Groton CT, US
Andrew Fensome - Harvard MA, US
Magdalena Korczynska - Somerville MA, US
Sophie Yvette Lavergne - Waterford CT, US
Allyn Timothy Londregan - Barrington RI, US
Vincent Mascitti - Westwood MA, US
David Walter Piotrowski - Waterford CT, US
Andre Shavnya - East Lyme CT, US
Meihua Mike Tu - Acton MA, US
Tao Wang - Sudbury MA, US
Hanna Maria Wisniewska - San Diego CA, US
Assignee:
Pfizer Inc. - New York NY
International Classification:
A61K 31/428
C07D 417/04
C07D 513/04
A61K 31/437
A61K 31/353
A61K 31/423
A61K 31/415
A61K 31/192
A61K 31/12
A61K 31/7105
Abstract:
This application includes a compound of Formula Ior a pharmaceutically acceptable salt thereof; wherein the variables R, R, R, R, X, Y and Z are as defined herein, pharmaceutical compositions comprising the compounds of Formula I and methods of treatment comprising administering to a patient in need thereof a compound of Formula I for the treatment of transthyretin amyloidosis and diseases related thereto.

Solid Forms Of 2-((4-((S)-2-(5-Chloropyridin-2-Yl)-2-Methylbenzo[D][1,3]Dioxol-4-Yl)Piperidin-1-Yl)Methyl)-1-(((S)-Oxetan-2-Yl)Methyl)-1H-Benzo[D]Imidazole-6-Carboxylic Acid, 1,3-Dihydroxy-2-(Hydroxymethyl)Propan-2-Amine Salt

View page
US Patent:
20230045419, Feb 9, 2023
Filed:
Dec 7, 2020
Appl. No.:
17/782478
Inventors:
- New York NY, US
Scott W. Bagley - Mystic CT, US
Wesley Dewitt Clark - Gales Ferry CT, US
John M. Curto - Mystic CT, US
David James Edmonds - Riehen, CH
Mark E. Flanagan - Gales Ferry CT, US
Kentaro Futatsugi - Sharon MA, US
David Andrew Griffith - Sudbury MA, US
Kim Huard - Berkeley CA, US
Yajing Lian - Waterford CT, US
Chris Limberakis - Pawcatuck CT, US
Allyn T. Londregan - Barrington RI, US
Alan M. Mathiowetz - Waltham MA, US
David Walter Piotrowski - Waterford CT, US
Roger B. Ruggeri - Waterford CT, US
Assignee:
Pfizer Inc. - New York NY
International Classification:
C07D 405/14
Abstract:
The invention provides solid forms of 2-((4-((S)-2-(5-chloropyridin-2-yl)-2-methylbenzo[d][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-1-(((S)-oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid, 1,3-dihydroxy-2-(hydroxymethyl)propan-2-amine salt for example, a hydrate (e.g. a monohydrate) crystalline form (e.g. Form 2 or Form 3) or an amorphous form; as well as pharmaceutical compositions, and the uses thereof in treating diseases, conditions or disorders modulated by GLP-1R in a mammal, such as a human.

Diacylglycerol Acyl Transferase 2 Inhibitors

View page
US Patent:
20210309646, Oct 7, 2021
Filed:
Jun 11, 2021
Appl. No.:
17/345064
Inventors:
- New York NY, US
Shawn Cabral - Groton CT, US
Matthew S. Dowling - Old Lyme CT, US
Kentaro Futatsugi - Qunicy MA, US
Kim Huard - Berkeley CA, US
Esther Cheng Yin Lee - Newton MA, US
Allyn T. Londregan - Barrington RI, US
Jana Polivkova - Mystic CT, US
David A. Price - Concord MA, US
Qifang Li - Stonington CT, US
Assignee:
Pfizer Inc. - New York NY
International Classification:
C07D 405/14
C07D 401/14
A61K 31/506
A61K 45/06
C07D 409/14
Abstract:
Compounds of Formula I that inhibit the activity of the diacylglycerol acyltransferase 2 (DGAT2) and their uses in the treatment of diseases linked thereto in animals are described herein.
Control profile
Allyn Timothy Londregan from Barrington, RI, age ~44 Get Report